Abstract
Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease. Nusinersen is the first pharmacologic therapy approved for treatment of SMA. More research is needed to understand the real-world economic benefits of nusinersen treatment. Healthcare utilization and costs of patients treated with nusinersen were investigated using US hospital-based administrative data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have